Reduction of enhanced rabbit intraocular pressure by instillation of pyroglutamic acid eye drops

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 6, 2013, Pages 1017-1023

  Ito, Yoshimasa ^a   Nagai, Noriaki ^a   Okamoto, Norio ^b   Shimomura, Yoshikazu ^b   Nakanishi, Kunio ^c   Tanaka, Ryuichiro ^c  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

2 hydroxypropyl cyclodextrin; Glaucoma; Nitric oxide; Pyroglutamic acid; Zinc

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; EYE DROPS; NITRIC OXIDE; PYROGLUTAMIC ACID; ZINC CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORNEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INSTILLATION; DRUG PENETRATION; EXPERIMENTAL RABBIT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; NONHUMAN; TREATMENT RESPONSE;

ANIMALS; AQUEOUS HUMOR; BETA-CYCLODEXTRINS; CORNEA; INTRAOCULAR PRESSURE; MALE; NITRIC OXIDE; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PYRROLIDONECARBOXYLIC ACID; RABBITS;

EID: 84878852801     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00159     Document Type: Article

References (35)

1. Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, Levene RZ, Maumenee AE, Pollack IP, Shaffer RN. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch. Ophthalmol., 98, 2163-2171 (1980).
2. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol., 99, 635-649 (1981).
3. Quigley HA. Number of people with glaucoma worldwide. Br. J. Ophthalmol., 80, 389-393 (1996).
4. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest. Ophthalmol. Vis. Sci., 46, 175-182 (2005).
5. Shimazaki A. Basis of anti-glaucoma agents. Nippon Yakurigaku Zasshi, 128, 250-254 (2006).
6. Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev., 52, 25-36 (2001).
7. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara HJ, Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J. Control. Release, 136, 247-253 (2009).
8. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther., 51, 155-194 (1991).
9. Van der Werf P, Meister A. The metabolic formation and utilization of 5-oxo-L-proline (L-pyroglutamate, L-pyrrolidone carboxylate). Adv. Enzymol. Relat. Areas Mol. Biol., 43, 519-556 (1975).
10. Abraham GN, Podell DN. Pyroglutamic acid. Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Mol. Cell. Biochem., 38 (Spec. No.), 181-190 (1981).
11. Oono S, Kurimoto T, Nakazawa T, Miyoshi T, Okamoto N, Kashimoto R, Tagami Y, Ito Y, Mimura O. Pyroglutamic acid promotes survival of retinal ganglion cells after optic nerve injury. Curr. Eye Res., 34, 598-605 (2009).
12. Iwata S, Ohtani Y, Osada E, Ogino H. Aspect on corneal permeability of bupranolol. Yakugaku Zasshi, 100, 402-406 (1980).
13. Sloan KB, Siver KG, Koch SA. The effect of vehicle on the diffusion of salicylic acid through hairless mouse skin. J. Pharm. Sci., 75, 744-749 (1986).
14. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4, 879-885 (1981).
15. Bonomi L, Tomazzoli L, Jaria D. An improved model of experimentally induced ocular hypertension in the rabbit. Invest. Ophthalmol., 15, 781-784 (1976).
16. Doane MG, Jensen AD, Dohlman CH. Penetration routes of topically applied eye medications. Am. J. Ophthalmol., 85, 383-386 (1978).
17. Sasaki H, Ichikawa M, Kawakami S, Yamamura K, Mukai T, Nishida K, Nakamura J. In-situ ocular absorption of ophthalmic beta-blockers through ocular membranes in albino rabbits. J. Pharm. Pharmacol., 49, 140-144 (1997).
18. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162 (1997).
19. Mueller BW, Brauns U. Solubilization of drugs by modified β-cyclodextrins. Int. J. Pharm., 26, 77-88 (1985).
20. Kristinsson JK, Fridriksdóttir H, Thórisdóttir S, Sigurdardóttir AM, Stefánsson E, Loftsson T. Dexamethasone- cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest. Ophthalmol. Vis. Sci., 37, 1199-1203 (1996).
21. Saarinen-Savolainen P, Järvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm. Res., 15, 1275-1280 (1998).
22. Jansen T, Xhonneux B, Mesens J, Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res., 7, 459-468 (1990).
23. Shah GB, Sharma S, Mehta AA, Goyal RK. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J. Cardiovasc. Pharmacol., 36, 169-175 (2000).
24. Kiel JW, Reitsamer HA, Walker JS, Kiel FW. Effects of nitric oxide synthase inhibition on ciliary blood flow, aqueous production and intraocular pressure. Exp. Eye Res., 73, 355-364 (2001).
25. Kiel JW. Modulation of choroidal autoregulation in the rabbit. Exp. Eye Res., 69, 413-429 (1999).
26. Ito Y, Nagai N, Shimomura Y. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit. Biol. Pharm. Bull., 33, 1574-1578 (2010).
27. Anjou CI. Influence of light on the 24-hour variation in aqueous flare density and intra-ocular pressure in normal rabbits' eyes. Acta Ophthalmol. (Copenh.), 39, 852-873 (1961).
28. Anjou CI. Physiological variations of the aqueous flare density in normal rabbits' eyes. Acta Ophthalmol. (Copenh.), 39, 507-524 (1961).
29. Rowland JM, Potter DE, Reiter RJ. Circadian rhythm in intraocular pressure: a rabbit model. Curr. Eye Res., 1, 169-173 (1981).
30. Gregory DS, Aviado DG, Sears ML. Cervical ganglionectomy alters the circadian rhythm of intraocular pressure in New Zealand white rabbits. Curr. Eye Res., 4, 1273-1279 (1985).
31. Rowland JM, Sawyer WK, Tittel J, Ford CJ. Studies on the circadian rhythm of IOP in rabbits: correlation with aqueous inflow and cAMP content. Curr. Eye Res., 5, 201-206 (1986).
32. McLaren JW, Trocme SD, Relf S, Brubaker RF. Rate of flow of aqueous humor determined from measurements of aqueous flare. Invest. Ophthalmol. Vis. Sci., 31, 339-346 (1990).
33. Smith SD, Gregory DS. A circadian rhythm of aqueous flow underlies the circadian rhythm of IOP in NZW rabbits. Invest. Ophthalmol. Vis. Sci., 30, 775-778 (1989).
34. Liu JH, Dacus AC, Bartels SP. Adrenergic mechanism in circadian elevation of intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci., 32, 2178-2183 (1991).
35. Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, Narumiya S, Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci., 42, 137-144 (2001).